An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment

NCT06497010 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: Biological: PD-1
DRUG: Biological: InnoPCV

Sponsor

The Affiliated Hospital Of Guizhou Medical University

Collaborators

[object Object]